Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G10 | O15496 | 1/20 | 0.52 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.52 |
| ▸ | PARP10 | Q53GL7 | 8/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.46 |
| ▸ | PARP15 | Q460N3 | 2/20 | 0.46 |
| ▸ | PARP2 | Q9UGN5 | 2/20 | 0.46 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | PARP4 | Q9UKK3 | 2/20 | 0.43 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.43 |
| ▸ | PARP16 | Q8N5Y8 | 1/20 | 0.43 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.43 |
| ▸ | PARP1 | P09874 | 3/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | BLM | P54132 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5323933 | 0.83 | KMT2A (0.49) | KMT2AALDH1A1POLBMAPTTDP1 | |
| SCHEMBL7366568 | 0.81 | PLA2G10 (0.59) | PLA2G10PLA2G2APARP10KMT2APARP15 | |
| SCHEMBL211305 | 0.81 | ALDH1A1 (0.54) | KMT2AALDH1A1POLBMAPTTSHR | |
| SCHEMBL3455668 | 0.80 | PLA2G10 (0.48) | PLA2G10PLA2G2APARP10KMT2APARP15 | |
| SCHEMBL31481194 | 0.79 | CA2 (0.57) | KMT2AMAPTCA2 | |
| SCHEMBL9142779 | 0.79 | KMT2A (0.59) | KMT2AALDH1A1MAPTHSD17B10L3MBTL1 | |
| SCHEMBL7039295 | 0.79 | KMT2A (0.46) | KMT2AALDH1A1MAPTL3MBTL1MEN1 | |
| SCHEMBL2857119 | 0.77 | ENPP2 (0.50) | PARP10PARP15PARP2PARP14PARP1 | |
| Carbamic Acid SCHEMBL27400265 | 0.77 | KMT2A (0.51) | PLA2G10PLA2G2AKMT2AALDH1A1MAPT | |
| SCHEMBL2154504 | 0.76 | KMT2A (0.47) | KMT2AMAPTTDP1L3MBTL1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 120 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1773768-B1 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | EXELIXIS INC (US) | 2018-08-22 | — | — | EP | claimed |
| EP-1904439-B1 | SPHINGOSINE KINASE INHIBITORS | APOGEE BIOTHECHNOLOGY CORP (US) | 2014-11-26 | — | — | EP | claimed |
| US-8664261-B2 | Organic compounds having cooling properties | GIVAUDAN S.A. (CH) | 2014-03-04 | — | — | US | claimed |
| US-8557800-B2 | Sphingosine kinase inhibitors | APOGEE BIOTECHNOLOGY CORPORATION (US) | 2013-10-15 | — | — | US | claimed |
| US-8377422-B2 | Carboxamide derivatives having cooling properties | GIVAUDAN S.A. (CH) | 2013-02-19 | — | — | US | claimed |
| US-20120196018-A1 | Organic Compounds | GIVAUDAN SA (CH) | 2012-08-02 | — | — | US | claimed |
| EP-2459010-A1 | IMPROVEMENTS IN OR RELATING TO ORGANIC COMPOUNDS | Givaudan SA (CH) | 2012-06-06 | — | — | EP | claimed |
| US-7968591-B2 | 1,3-disubstituted 4-methyl-1H-pyrrole-2-carboxamides and their use in medicaments | GRUENENTHAL GMBH (DE) | 2011-06-28 | — | — | US | claimed |
| EP-2035375-B1 | 1,3-DISUBSTITUTED 4-METHYL-1H-PYRROLE-2-CARBOXAMIDES AND THEIR USE FOR THE MANUFACTURE OF MEDICAMENTS | GRUENENTHAL GMBH (DE) | 2011-01-19 | — | — | EP | claimed |
| US-20100297038-A1 | Benzimidazole Derivatives And Their Use As Cooling Agents | GIVAUDAN S.A. (CH) | 2010-11-25 | — | — | US | claimed |
| WO-2007141039-A1 | 1,3-DISUBSTITUTED 4-METHYL-1H-PYRROLE-2-CARBOXAMIDES AND THEIR USE FOR THE MANUFACTURE OF MEDICAMENTS | Grünenthal GmbH (DE) | 2007-12-13 | — | — | WO | claimed |
| EP-1773768-A2 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | Exelixis, Inc. (US) | 2007-04-18 | — | — | EP | claimed |
| WO-2006138660-A2 | SPHINGOSINE KINASE INHIBITORS | APOGEE BIOTECHNOLOGY CORPORATION (US) | 2006-12-28 | — | — | WO | claimed |
| US-20060287317-A1 | SPHINGOSINE KINASE INHIBITORS | APOGEE BIOTECHNOLOGY CORPORATION (US) | 2006-12-21 | — | — | US | claimed |
| US-7009052-B2 | Sulfonamide derivatives | WARNER LAMBERT COMPANY LLC (US) | 2006-03-07 | — | — | US | claimed |
| WO-2006012642-A2 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | EXELIXIS, INC. (US) | 2006-02-02 | — | — | WO | claimed |
| US-20050182050-A1 | Therapeutic heterocyclic compounds | ASTRAZENECA AB (SE) | 2005-08-18 | — | — | US | claimed |
| US-20050004367-A1 | Sulfonamide derivatives | DU DANIEL Y (US) | 2005-01-06 | — | — | US | claimed |
| US-6812225-B2 | PYSCHOLOGICAL DISORDERS; ANTIDEPRESSANTS | ASTRAZENECA AB (SE) | 2004-11-02 | — | — | US | claimed |
| US-20030013708-A1 | Therapeutic heterocyclic compounds | ASTRAZENECA AB (SE) | 2003-01-16 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100297038-A1 | Benzimidazole Derivatives And Their Use As Cooling Agents | OR10J3, H1-3, ORC3 | PLA2G10 4256/4885PLA2G2A 4682/4885PARP10 1618/4885 |
| US-20060287317-A1 | SPHINGOSINE KINASE INHIBITORS | SPHK1, SPHK2, S1PR1 | PLA2G10 1026/4885PLA2G2A 1397/4885PARP10 1507/4885 |
| US-20050004367-A1 | Sulfonamide derivatives | AR, SULT2A1, SHBG | PLA2G10 3539/4885PLA2G2A 3896/4885PARP10 836/4885 |
| US-20050182050-A1 | Therapeutic heterocyclic compounds | HTR1B, HTR1D, HTR1A | PLA2G10 3959/4885PLA2G2A 4072/4885PARP10 2519/4885 |
| US-20030013708-A1 | Therapeutic heterocyclic compounds | HTR1A, HTR1D, HTR1B | PLA2G10 4106/4885PLA2G2A 4315/4885PARP10 2526/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.